Floatz logo

Xeomin®

Prostatitis

Daniel Stephan EngelerPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Prostatitis cohort.

Asset / SponsorPhaseRating
LIDOCAINE
University of Washington
Phase 4BB
DEXAMETHASONE
University of Washington
Phase 4BB
Sildenafil
University of Washington
Phase 4B
Fosfomycin
University Hospital, Rouen
Phase 3B
Gralise
Shirley Ryan AbilityLab
Phase 4B

View all 11 →

Same molecule, other indications

Xeomin® is also rated in:

Muscle SpasticityDormant
BBB
Indicative ·
79 / 100
View asset →
Migraine DisordersDormant
BBB
Indicative ·
77 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →